Actionable news
0
All posts from Actionable news
Actionable news in CORI: CORIUM INTERNATIONAL Inc,

Corium to Present Clinical Results from Pilot Bioequivalence Study of Once-weekly Corplex™ Donepezil Transdermal System at Alzheimer's Association International Conference® 2017

MENLO PARK, Calif., July 06, 2017 (GLOBE NEWSWIRE) -- Corium International, Inc. (CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced that Parminder "Bobby" Singh, Ph.D., Corium's Chief Technology Officer and Vice President, Research and Development, will present the clinical results from a bioequivalence (BE) study of Corium's once-weekly Corplex Donepezil product candidate at the Alzheimer's Association International Conference 2017 (AAIC) in London, UK, on July 18, 2017.

The pilot BE study was a six-month, three-period, randomized crossover study comparing the steady-state pharmacokinetic profiles of once-daily oral Aricept® with two Corplex Donepezil transdermal patches that differed only in size. Preliminary results from this study were reported on May 11, 2017.

Corium is planning to start its pivotal BE study later this year and remains on track to file a Section 505(b)(2) New Drug Application (NDA) for the product candidate in 2018. The pivotal study will be a simpler, two-way crossover design compared to the three-way crossover pilot study.

Poster Presentation...


More